Indication
Recurrent non-small cell lung cancer
3 clinical trials
3 products
Product
LYL797Clinical trial
A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults With Relapsed and/or Refractory Solid-Tumor MalignanciesStatus: Recruiting, Estimated PCD: 2025-03-01
Product
BDTX-4933Clinical trial
A Phase 1, Open-label Study of Oral BDTX-4933 in Patients With KRAS, BRAF and Other Select RAS/MAPK Mutation Positive NeoplasmsStatus: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Single-arm, Open-label, Phase 2 Study of Dacomitinib With or Without Dose Titration for the First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Subjects With an Epidermal Growth Factor Receptor (EGFR) Activation MutationStatus: Active (not recruiting), Estimated PCD: 2026-03-31
Product
Dacomitinib